Combination Therapy Shows Promise in Oligorecurrent Pelvic-Node Relapses of Prostate Cancer

By Reuters Staff

July 23, 2021

NEW YORK (Reuters Health) - The combination of high-dose salvage pelvic radiotherapy and six months of androgen-deprivation therapy (ADT) shows promise for oligorecurrent pelvic nodal relapse of prostatic cancer, with nearly half of patients in complete remission three years following treatment.

Findings from the French multicenter phase-2 OLIGOPELVIS GETUG P07 study are online now in European Urology.

"Oligorecurrent pelvic nodal relapse of prostatic cancer is a challenge for regional salvage treatments," Dr. Stephane Supiot of Institut de Cancerologie de l'Ouest, in Nantes, France, and colleagues note in their article.

The OLIGOPELVIS GETUG P07 study tested combined salvage radiotherapy and six-months of ADT in 67 men (median age, 68 years) with oligorecurrent (five or fewer) pelvic-node relapses of prostate cancer detected by fluorocholine-PET-CT imaging. Half of the patients had received prior radiation to the prostate.

After a median follow-up of 49 months, the progression-free survival (PFS) rate was 81% at two years and 58% at three years. Median PFS was 45 months.

Median biochemical relapse-free survival (BRFS) was 26 months. The BRFS rate was 58% at two years and 46% at three years.

The combined treatment was well tolerated; grade-2+ genitourinary and gastrointestinal toxicities at two years were 10% and 2%, respectively.

The study shows that combining high-dose salvage pelvic radiotherapy with ADT can prolong tumor control in oligorecurrent pelvic-node relapses of prostate cancer with "limited toxicity," the study team concludes.

This "initial evidence of benefit" needs to be confirmed isn a randomized trial, they add.

This study received an educational grant from Astellas Pharmaceuticals, France. The funder had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. The authors have declared no conflicts of interest.

SOURCE: European Urology, online July 8, 2021.